EA200501382A1 - Соединения и способы лечения клеточных пролиферативных заболеваний, ретинопатий и артрита - Google Patents

Соединения и способы лечения клеточных пролиферативных заболеваний, ретинопатий и артрита

Info

Publication number
EA200501382A1
EA200501382A1 EA200501382A EA200501382A EA200501382A1 EA 200501382 A1 EA200501382 A1 EA 200501382A1 EA 200501382 A EA200501382 A EA 200501382A EA 200501382 A EA200501382 A EA 200501382A EA 200501382 A1 EA200501382 A1 EA 200501382A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
derivative
alkyl
retinopathy
arthritis
Prior art date
Application number
EA200501382A
Other languages
English (en)
Inventor
Бертран Леблон
Сильвер Пети
Виржини Пикар
Тьерри Таверн
Фабьен Швайгхоффер
Original Assignee
ЭксонХит Терапьютикс СА
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭксонХит Терапьютикс СА filed Critical ЭксонХит Терапьютикс СА
Publication of EA200501382A1 publication Critical patent/EA200501382A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, имеющим общую формулу (I), и их применению особенно в фармацевтической промышленности. Изобретение описывает соединения, имеющие антипролиферативную и антиангиогенную активность, а также способы для лечения различных заболеваний, связанных с аномальной клеточной пролиферацией, включая злокачественную опухоль, или связанных с нерегулируемым ангиогенезом, включая рост и метастазирование солидных опухолей, болезни глаз и особенно ретинопатии, или артрит, введением указанных соединений. Кроме того, оно имеет отношение к фармацевтическим композициям, содержащим указанные соединения, в частности, применимые для лечения злокачественных опухолей (таких как лейкоз), болезней глаз и артрита.Отчет о международном поиске был опубликован 2005.01.06.
EA200501382A 2003-02-28 2004-02-27 Соединения и способы лечения клеточных пролиферативных заболеваний, ретинопатий и артрита EA200501382A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20030290490 EP1471063A1 (en) 2003-02-28 2003-02-28 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
PCT/IB2004/000926 WO2004076445A2 (en) 2003-02-28 2004-02-27 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis

Publications (1)

Publication Number Publication Date
EA200501382A1 true EA200501382A1 (ru) 2006-02-24

Family

ID=32921633

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501382A EA200501382A1 (ru) 2003-02-28 2004-02-27 Соединения и способы лечения клеточных пролиферативных заболеваний, ретинопатий и артрита

Country Status (10)

Country Link
US (2) US7514432B2 (ru)
EP (2) EP1471063A1 (ru)
JP (1) JP4648894B2 (ru)
CN (1) CN1747952A (ru)
AT (1) ATE335734T1 (ru)
AU (1) AU2004215577A1 (ru)
CA (1) CA2516239A1 (ru)
DE (1) DE602004001864T2 (ru)
EA (1) EA200501382A1 (ru)
WO (1) WO2004076445A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1471063A1 (en) * 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis
US7517890B2 (en) 2003-11-20 2009-04-14 Children's Hospital Medical Center GTPase inhibitors and methods of use
EP1814553A4 (en) 2004-11-19 2009-10-28 Childrens Hosp Medical Center GTPASE INHIBITORS AND THEIR USE IN CONTROLLING PLATELET HYPERACTIVITY
US20070027146A1 (en) * 2005-07-27 2007-02-01 Exonhit Therapeutics Sa Methods of treating nervous disorders
CA2617056A1 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
CN101874032B (zh) * 2007-11-26 2013-02-06 富山化学工业株式会社 二氮杂萘衍生物一水合物及其制备方法
CA2733931A1 (en) * 2008-08-15 2010-02-18 Burnham Institute For Medical Research Composition and methods for the design and development of metallo-enzyme inhibitors
TWI518084B (zh) * 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
US8900601B2 (en) 2010-03-31 2014-12-02 Jennifer Bartels Permeable mixtures, methods and compositions for the skin
US8771682B2 (en) 2011-04-26 2014-07-08 Technische Universtität Dresden Methods and compositions for reducing interleukin-4 or interleukin-13 signaling
WO2014170712A1 (en) 2013-04-15 2014-10-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Rac-1 inhibitors or pi3k inhibitors for preventing intestinal barrier dysfunction
US10155001B2 (en) 2013-06-14 2018-12-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) RAC1 inhibitors for inducing bronchodilation
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
CN105424666B (zh) * 2015-12-11 2018-06-29 山东省科学院生物研究所 一种快速、定量评价化合物对斑马鱼血管生成促进作用的方法
AR110412A1 (es) * 2016-12-22 2019-03-27 Orion Corp Inhibidores de la cyp11a1
WO2019023315A2 (en) 2017-07-25 2019-01-31 Geneyus LLC RAC INHIBITORS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812584A (en) * 1984-07-11 1989-03-14 G. D. Searle & Co. Aralkoxy and aryloxyalkoxy kojic acid derivatives
US4644071A (en) * 1984-07-11 1987-02-17 G. D. Searle & Co. Aralkoxy and aryloxyalkoxy kojic acid derivatives
ZA858493B (en) * 1984-11-12 1986-07-30 Yamanouchi Pharma Co Ltd Heterocyclic compounds and process of producing them
US6552073B1 (en) * 2002-03-01 2003-04-22 Exonhit Therapeutics Sa Compounds and methods of treating cell proliferative diseases
EP1471063A1 (en) * 2003-02-28 2004-10-27 Exonhit Therapeutics S.A. Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis

Also Published As

Publication number Publication date
US20060183749A1 (en) 2006-08-17
US7514432B2 (en) 2009-04-07
EP1597253B1 (en) 2006-08-09
WO2004076445A2 (en) 2004-09-10
CA2516239A1 (en) 2004-09-10
ATE335734T1 (de) 2006-09-15
JP4648894B2 (ja) 2011-03-09
US20090216014A1 (en) 2009-08-27
WO2004076445A3 (en) 2005-01-06
DE602004001864D1 (de) 2006-09-21
JP2006519221A (ja) 2006-08-24
EP1597253A2 (en) 2005-11-23
AU2004215577A1 (en) 2004-09-10
DE602004001864T2 (de) 2007-09-06
EP1471063A1 (en) 2004-10-27
CN1747952A (zh) 2006-03-15

Similar Documents

Publication Publication Date Title
EA200501382A1 (ru) Соединения и способы лечения клеточных пролиферативных заболеваний, ретинопатий и артрита
PE20221264A1 (es) Inhibidores de egfr
AR039209A1 (es) Derivados de indolilmaleimida
PE20070839A1 (es) Derivados de indolobenzazepina como inhibidores de ns5b de vhc
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
CO5550451A2 (es) Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas
MY194461A (en) N-[2-(1-benzylpiperidin-4-yl)4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
NO971278D0 (no) Naftylforbindelser, mellomprodukter, fremgangsmåter, sammensetninger og metoder
AR058701A1 (es) Derivados de piracinil-s-espiro-oxacinoquinolin-pirimidin-triona como agentes antibacterianos
ATE544756T1 (de) Substituierte carbinolverbindungen
HRP20050191B1 (hr) Novi derivati benzoimidazola korisni kao antiproliferativna sredstva
ES2171109A1 (es) Derivados de 4-fenil-piridina.
NO951160D0 (no) Bifenylderivat, fremstilling derav, og middel og preparat omfattende bifenylderivat
KR950704328A (ko) 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists)
AR041273A1 (es) Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
HK1145834A1 (en) Phenylpyrazole derivatives
DE69531154D1 (de) Neuroprotektive 3-(piperidinyl-1)-chroman-4,7-diol und 1-(4-hyphoxyphenyl)-2-(piperidinyl-1)-alkanolderivate
ES2107212T3 (es) Derivados de 1,4-benzoxazina como abridores de los canales de potasio.
NO980395L (no) Naftyl og dihydronaftyl mellomprodukter, forbindelser, sammensetninger og metoder
NO20071319L (no) Fremgangsmate for fremstilling av isotiazolderivater.
ATE382036T1 (de) (1-indanon)-(1,2,3,6-tetrahydropyridin)derivat
DK0641793T3 (da) 5-amino-8-methyl-7-pyrrolidinylquinolin-3-carboxylsyrederivat
NO961797L (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
IT1250362B (it) Derivati dell'1-3-diossolano quali agenti per la riduzione del colesterolo